In vitro safety pharmacology profiling is an integrated essential component of drug discovery and used extensively throughout the discovery process to predict clinical adverse effects to reduce unwarranted attrition. However, it remains challenging to build and integrate fit-for-purpose panel of targets with in vitro pharmacological effects are translatable to ADRs. Activation of MrgX2, a GPCR expressed on mast cells, leads to degranulation and histamine release. MrgX2 binds promiscuously to basic peptides and small molecules, resulting in acute histamine-like adverse drug reactions, both in man and in mammalian species used in drug toxicology.
In this webinar Dr. Andrew J. Brown at GSK, discussed how knowledge of MrgX2 activity across a panel of mammalian species can be integrated into safety panel off-target selection to meet the specific needs of drug discovery programs.
With over 40 years of in vitro safety pharmacology expertise testing tens-of-thousands client compounds, Eurofins Discovery experienced team of scientists can work hand in hand during the off-target selection and panel design stage and provide valuable input in the data interpretation stage, as well as recommend the best next step in your study design to advance your program successfully.
About Webinar Speaker
Dr. Andrew J. Brown – Fellow at GlaxoSmithKline
Dr. Brown has been involved in drug discovery for 20+ years. Andrew received a Ph.D. at the University of Edinburgh, then joined GlaxoWellcome. Currently he oversees secondary pharmacology at GSK, and consults with the UK Home Office.
Learn more: www.eurofinsdiscoveryservices.com/services/safety-and-efficacy/
0 Comments